These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy. Hsu JY; Wakelee HA BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219 [TBL] [Abstract][Full Text] [Related]
3. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. de Gramont A; Van Cutsem E Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835 [TBL] [Abstract][Full Text] [Related]
4. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Shih T; Lindley C Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999 [TBL] [Abstract][Full Text] [Related]
5. Treatment of bevacizumab-induced hypertension by amlodipine. Mir O; Coriat R; Ropert S; Cabanes L; Blanchet B; Camps S; Billemont B; Knebelmann B; Goldwasser F Invest New Drugs; 2012 Apr; 30(2):702-7. PubMed ID: 20878444 [TBL] [Abstract][Full Text] [Related]
6. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Grothey A; Ellis LM Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556 [TBL] [Abstract][Full Text] [Related]
7. [Bevacizumab and arterial hypertension or proteinuria: management]. Senellart H; Bennouna J Rev Mal Respir; 2008 Jun; 25(6):767-72. PubMed ID: 18772832 [TBL] [Abstract][Full Text] [Related]
8. Angiogenesis inhibition in the treatment of lung cancer. Vokes E; Herbst R; Sandler A Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 23):1-10; quiz 11-2. PubMed ID: 17143257 [TBL] [Abstract][Full Text] [Related]
9. Acute renal failure in a patient receiving anti-VEGF therapy for advanced non-small cell lung cancer. Zhao J; Li H; Wang M J Thorac Oncol; 2009 Sep; 4(9):1185-7. PubMed ID: 19704343 [No Abstract] [Full Text] [Related]
10. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer. Chase JL Pharmacotherapy; 2008 Nov; 28(11 Pt 2):23S-30S. PubMed ID: 18980549 [TBL] [Abstract][Full Text] [Related]
11. Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer. Lyseng-Williamson KA; Robinson DM BioDrugs; 2006; 20(3):193-5. PubMed ID: 16724868 [TBL] [Abstract][Full Text] [Related]
12. Bevacizumab in the treatment of metastatic colorectal cancer. Caprioni F; Fornarini G Future Oncol; 2007 Apr; 3(2):141-8. PubMed ID: 17381413 [TBL] [Abstract][Full Text] [Related]
20. The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit? Eskens FA; Sleijfer S Eur J Cancer; 2008 Nov; 44(16):2350-6. PubMed ID: 18789679 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]